Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Rejects Patents For GSK Diabetes Drug, Pfizer Anti-Cholesterol

This article was originally published in PharmAsia News

Executive Summary

India's patent authority turned down protection for GlaxoSmithKline's diabetes and Pfizer's cholesterol drugs, exposing them to generic competition. The Delhi Patent Office said GSK did not make a case that its Avandia (rosiglitazone) was more efficacious than a previous version, freeing generics by Dr. Reddy's Laboratories, Sun Pharma and Torrent Pharma. The office also rejected Pfizer's Caduet, which combines its Norvasc (amlodipine) and Lipitor (atorvastatin). Torrent raised objections about a Caduet patent and the Patent Office agreed. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071416

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel